Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > OA & Back pain worth
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(35)
•••
Comment by RjM2018on Mar 19, 2021 1:27am
373 Views
Post# 32835774

RE:RE:RE:RE:RE:RE:RE:OA & Back pain worth

RE:RE:RE:RE:RE:RE:RE:OA & Back pain worth Solid Post Mugsy. 

I agree with you. From a strategic perspective it is now increasingly important to accelarate development of all other candidate molecules. After researching 15+ deals in the rare disease space, the platform play is the way to command more money in case of a buyout. 

When consultants perform due diligence reports they build out product profiles to solicit input from KOL on how such a product would impact their prescribing behaviors. Without human data, these reports are based on hypothetical situations and therefore not overly reliable in determining value of the molecule (ie: capture of market share). If you recall back to 346 - it was determined this would be a gold standard product - this was possible was because we had supportive Phase 2 human data to base the product profile on...basically the faster we can gather 352  phase 1 data, the better and perform such DD reports the better. 

just a thought. 




 



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities